Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug

Twelve years ago, Takeda became the first major Asian pharma company to buy into Alnylam’s pioneering RNAi platform with a landmark $1 billion alliance. Two FDA approvals and a slew of new deals for the field later, the Japanese drugmaker is making a new $1.04 billion bet on a rare disease program from a J&J-partnered RNAi player.